Answers are grounded in this paper and cite their sources.
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91phox) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance. Stein and colleagues report on the comprehensive preclinical and safety studies that they conducted in order to transition a self-inactivating gammaretroviral vector into the clinic for use in subjects with X-linked chronic granulomatous disease. Their studies included assessment of dosage requirements, therapeutic efficacy, and resistance to transgene silencing and genotoxic potential.
No takes yet. Share an insight, caveat, or question.
Stein et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: